Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 9, 2014, Pages 2426-2433

  Chilton, C H ^a   Crowther, G S ^a   Todhunter, S L ^a   Nicholson, S ^a   Freeman, J ^b   Chesnel, L ^c   Wilcox, M H ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

Chemostat; Recurrence; Ribotype 027

Indexed keywords

AGAR; BACTERIAL TOXIN; CLINDAMYCIN; CYTOTOXIN; DAPTOMYCIN; SUROTOMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; CYCLOPEPTIDE; LIPOPEPTIDE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL COUNT; BACTERIAL SPORE; BACTERIAL VIABILITY; BACTEROIDES FRAGILIS; BIFIDOBACTERIUM; BIOASSAY; CHEMOSTAT; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG EFFICACY; ENTEROCOCCUS; FECES; IN VITRO STUDY; INTESTINE FLORA; LACTOBACILLUS; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STEADY STATE; TANDEM MASS SPECTROMETRY; VEGETATIVE GROWTH; CLOSTRIDIUM INFECTIONS; DRUG EFFECTS; GASTROINTESTINAL TRACT; HUMAN; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; THEORETICAL MODEL; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; GASTROINTESTINAL TRACT; HUMANS; LIPOPEPTIDES; MODELS, THEORETICAL; PEPTIDES, CYCLIC; TREATMENT OUTCOME;

EID: 84905977547     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku141     Document Type: Article

References (21)

1. Wiegand PN, Nathwani D, Wilcox MH et al. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect 2012; 81: 1-14.
2. Ghantoji SS, Sail K, Lairson DR et al. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect 2010; 74: 309-18.
3. Al-Nassir WN, Sethi AK, Nerandzic MM et al. Comparison of clinical and microbiological response to treatment of Clostridium difficile associated disease with metronidazole and vancomycin. Clin Infect Dis 2008; 47: 56-62.
4. Baines SD, O'Connor R, Freeman J et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008; 62: 1046-52.
5. Barbut F, Richard A, Hamadi K et al. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000; 38: 2386-8.
6. Crook DW, Walker AS, Kean Y et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis 2012; 55 Suppl 2: S93-103.
7. Patino H, Stevens C, Louie T et al. Efficacy and safety of the lipopeptide CB-183,315 for the treatment of Clostridium difficile infection. In: Abstracts of the Fifty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2011. Abstract K-205a, p. 278. American Society for Microbiology, Washington, DC, USA.
8. MacFarlane GT, Macfarlane S, Gibson GR. Validation of a three-stage compound continuous culture system for investigating the effect of retention time on the ecology and metabolism of bacteria in the human colon. Microb Ecol 1998; 35: 180-7.
9. Freeman J, O'Neill FJ, Wilcox MH. Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut. J Antimicrob Chemother 2003; 52: 96-102.
10. Freeman J, Baines SD, Jabes D, Wilcox MH. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother 2005; 56: 717-25.
11. Chilton CH, Freeman J, Crowther GS et al. Co-amoxiclav induces proliferation and cytotoxin production of Clostridium difficile ribotype 027 in a human gut model. J Antimicrob Chemother 2012; 67: 951-4.
12. Baines SD, Freeman J, Wilcox MH. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model. J Antimicrob Chemother 2005; 55: 974-82.
13. Baines SD, Saxton K, Freeman J, Wilcox MH. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother 2006; 58: 1062-5.
14. Baines SD, O'Connor R, Saxton K et al. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. J Antimicrob Chemother 2008; 62: 1078-85.
15. Chilton CH, Crowther GS, Freeman J et al. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure. J Antimicrob Chemother 2014; 69: 451-62.
16. Freeman J, Baines SD, Saxton K, Wilcox MH. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J Antimicrob Chemother 2007; 60: 83-91.
17. Baines SD, Freeman J, Wilcox MH. Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection. Antimicrob Agents Chemother 2009; 53: 2202-4.
18. Chilton CH, Freeman J, Crowther GS et al. Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model. J Antimicrob Chemother 2012; 67: 2434-7.
19. Deane J, Chesnel L, Sahme D. In vitro susceptibility testing and activity of surotomycin against Clostridium difficile isolates from a phase 2 clinical trial. In: Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, 2013. Abstract E1176, p. 116. American Society for Microbiology, Washington, DC, USA.
20. Hurless K, Cadnum JL, Chesnel L et al. Effect of surotomycin, a novel cyclic lipopeptide antibiotic, on intestinal colonization with vancomycin-resistant enterococci and Klebsiella pneumoniae in mice. In: Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, 2013. Abstract F628, p. 116. American Society for Microbiology, Washington, DC, USA.
21. Cannon K, Byrne B, Happe J et al. Enteric microbiome profiles during a phase 2 clinical trial of CB183,315 vs vancomycin for treatment of Clostridium difficile infection. In: Abstracts of the Twenty-third European Congress of Clinical Microbiology and Infectious Diseases, London, 2012. Abstract P2250, p. 180. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.